Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Journal Scan / Research · May 04, 2021

Study in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance to Enzalutamide

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Phase 2 Multicenter Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer to Identify Mechanisms Driving Resistance
Clin. Cancer Res 2021 Apr 13;[EPub Ahead of Print], RR McKay, L Kwak, J Crowdis, JM Sperger, SG Zhao, W Xie, L Werner, RT Lis, Z Zhang, XX Wei, JM Lang, EM Van Allen, RS Bhatt, EY Yu, PS Nelson, GJ Bubley, B Montgomery, ME Taplin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading